News | Heart Valve Technology | June 11, 2015

Initial Outcomes Favorable for Transcatheter Mitral Repair With Abbott's MitraClip

Study data presented at ACC shows 93 percent of patients experienced significant decrease in mitral leakage

MitraClip, ACC, TVT registry, STS, Betty Vaughn

June 11, 2015 - Outcomes from the initial commercial experience of transcatheter mitral valve repair (TMVR) with Abbott's MitraClip were deemed favorable in a late-breaking clinical trial session at the American College of Cardiology's (ACC) 64 th annual scientific session and expo in March.

About three years ago, Betty Vaughn of Golden Valley, Minnesota, started to feel light-headed, fatigued and out of breath when she walked up and down the stairs. After visiting her doctor, the 89-year-old was diagnosed with degenerative mitral regurgitation (DMR), a heart condition in which the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart.  After her diagnosis, Paul Sorajja, M.D., cardiologist at Abbott Northwestern Hospital in Minneapolis, performed a TMVR procedure on Vaughn - who was not a good candidate for surgery - using Abbott's MitraClip in October 2014. Now, just months after the procedure, Vaughn has resumed many of the activities she loves, like working in the yard and playing cards with friends.

MitraClip treats people with DMR, which is a condition involving a dysfunction of the heart's mitral valve. It is a treatment option for people who are not good candidates for surgery, the current standard of care, because of their advanced age, frailty or other complicating factors. In the United States, mitral regurgitation (MR) is the most common valve disease, affecting nearly one in 10 people age 75 and older. People with MR often have difficulty with everyday activities, such as climbing stairs, and may require long periods of rest due to fatigue.   

In the study, a transcatheter valve therapy (TVT) registry formed from a partnership with the Society of Thoracic Surgeons (STS) and ACC, researchers evaluated data from 564 people with TMVR who were treated with MitraClip following U.S. Food and Drug Administration (FDA) approval of the device in October 2013 through August 2014. The data continue to support the use of MitraClip, with successful treatment for 93 percent of people in the study. The treated group's median age was 83 years old, and they were not candidates for surgery because they were too frail or had other complicating factors. Sorajja, the lead investigator for this study, shared the data at the ACC session.

"The results of this MitraClip study are very favorable and consistent with the results we saw in studies prior to the therapy's U.S. approval," Sorajja said. "The results show clinically meaningful reduction in the severity of mitral regurgitation and improvement in the overall health of very sick people with prohibitive risk DMR who have no other meaningful options to improve their lives."

In the ACC presentation, Sorajja concluded that treatment with MitraClip for prohibitive risk patients with symptomatic MR is durable in a real-world commercial setting. Key findings from the 564 patients treated with the MitraClip device demonstrated the following:

  • Prior to treatment, more than 90 percent of patients had a mitral regurgitation grade of 3 or 4, indicating significant leakage of the mitral valve. After treatment with MitraClip, 93 percent of patients achieved an MR grade of less than or equal to 2, with 63.6 percent at a grade of less than or equal to 1, demonstrating a significant decrease in leakage;
  • Average length of stay in the hospital was 3 days, with 82 percent discharged home; and
  • Adverse events and procedural complications were low, consistent with clinical trial experience.

 

For more information: www.mitraclip.com

Related Content

Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Overlay Init